In this paper, we introduce the elimination algorithm, which performs, in linear time, minimal model finding and minimal model checking for a significant subclass of positive CNF theories which we call positive head-cycle-free (HCF) theories.
Nonetheless, it is known that a significant subclass of \ \textbf{NP}\ -complete problems possess polynomial time approximation algorithms -- i.e. algorithms which are guaranteed to find a solution which is within a certain constant factor of optimality.
Pathologists reading this list may agree that the tumors from this list include clinically distinct and significant subclasses of tumors and would be welcome additions to a truly comprehensive nomenclature of neoplastic entities.
Gene expression analyses across glioblastoma multiforme tumors taken in toto has shown that there are significant subclasses of glioblastoma that differ in large ways in gene expression patterns [ 27, 32, 33].
The most significant biological function classification was in skeletal and muscular development and function with the most significant subclass being skeletal development (corrected p-value of 2.22×10−9) (Table S7).
Backward selection procedure was used, with removal criterion P>0.10, to identify a subclass of significant clinical variables.
A backward selection procedure identified the subclass of significant variables among the following: stage (IIB vs III), Breslow (0 2 vs 2.1 4>4), Clark (II III vs IV vs V), ulceration (No vs Yes), regression (No vs Yes), lymph node status (No vs Yes) primary tumour location, sex (male vs female), age (<52 vs 52).
This procedure identified a subclass of significant variables among the following: treatment group (FOLFIRI vs XELIRI), age (≥60 vs <60), sex (women vs men), PS (1 2 vs 0), adjuvant chemotherapy (yes vs no), primary site (rectal vs colon), number of metastatic sites (≥3 vs 2 vs 1) and NO, OPN, TGF-β1 and VEGF-A plasma concentrations (high vs low).
Those developing DSSs might reject our blanket category, claiming significant differences between subclasses of these systems (e.g. how a specific tool works or is developed), in the same way that a chemist will recognise molecular differences between the individual drugs that form a single therapeutic class.
However, sporadic reports in which significant therapeutic potential was achieved [ 4- 6] suggest that a distinct subclass of patients with an infectious-associated phenotype may exist.
or a subclass of BUILT-IN-CLASS.
